Segment Information - Schedule of Financial Information for the Company’s Reportable Segments (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Segment Reporting Information [Line Items]
Revenue	$ 44,403	$ 37,548
Other revenue	584	212
Provision for credit losses	12,756	1,912
Loss on impairment of intangible assets	5,771	0
Impairment of goodwill	0	8,404
Interest expense	4,685	1,849
Pharmaceutical manufacturing, research and development	2,203	3,436
Change in fair value of acquisition-related contingent consideration	(4,900)	(6,300)
Depreciation and amortization expense	1,399	2,577
General and administrative expense	11,487	11,232
Other income (expense), net	6,786	(37)
Income tax expense (benefit)	4,884	(1,274)
Net income (loss)	13,488	15,887
Holding Company and Other
Segment Reporting Information [Line Items]
Revenue	0	0
Other revenue	0	6
Provision for credit losses	0	0
Loss on impairment of intangible assets	0
Impairment of goodwill		0
Interest expense	3,599	864
Pharmaceutical manufacturing, research and development	0	0
Change in fair value of acquisition-related contingent consideration	0	0
Depreciation and amortization expense	83	52
General and administrative expense	8,071	7,830
Other income (expense), net	(408)	0
Income tax expense (benefit)	4,884	(1,274)
Net income (loss)	(17,045)	(7,466)
Finance Receivables | Operating Segments
Segment Reporting Information [Line Items]
Revenue	40,787	36,346
Other revenue	553	204
Provision for credit losses	12,756	1,912
Loss on impairment of intangible assets	0
Impairment of goodwill		0
Interest expense	1,078	982
Pharmaceutical manufacturing, research and development	0	0
Change in fair value of acquisition-related contingent consideration	0	0
Depreciation and amortization expense	0	0
General and administrative expense	449	527
Other income (expense), net	7,194	(13)
Income tax expense (benefit)	0	0
Net income (loss)	34,251	33,116
Pharmaceutical Development and Other | Operating Segments
Segment Reporting Information [Line Items]
Revenue	3,616	1,202
Other revenue	31	2
Provision for credit losses	0	0
Loss on impairment of intangible assets	5,771
Impairment of goodwill		8,404
Interest expense	8	3
Pharmaceutical manufacturing, research and development	2,203	3,436
Change in fair value of acquisition-related contingent consideration	(4,900)	(6,300)
Depreciation and amortization expense	1,316	2,525
General and administrative expense	2,967	2,875
Other income (expense), net	0	(24)
Income tax expense (benefit)	0	0
Net income (loss)	$ (3,718)	$ (9,763)